Advertisement
New Zealand markets closed

  • NZX 50

    11,367.51
    +37.31 (+0.33%)
     

  • NZD/USD

    0.6211
    +0.0054 (+0.88%)
     

  • NZD/EUR

    0.5700
    +0.0052 (+0.92%)
     

  • ALL ORDS

    7,285.10
    -12.60 (-0.17%)
     

  • ASX 200

    7,073.20
    -14.10 (-0.20%)
     

  • OIL

    74.38
    -1.58 (-2.08%)
     

  • GOLD

    2,091.70
    +34.50 (+1.68%)
     

  • NASDAQ

    15,997.58
    +49.71 (+0.31%)
     

  • FTSE

    7,529.35
    +75.60 (+1.01%)
     

  • Dow Jones

    36,245.50
    +294.61 (+0.82%)
     

  • DAX

    16,397.52
    +182.09 (+1.12%)
     

  • Hang Seng

    16,830.30
    -212.58 (-1.25%)
     

  • NIKKEI 225

    33,431.51
    -55.38 (-0.17%)
     

  • NZD/JPY

    91.1520
    -0.0140 (-0.02%)
     

Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

For the quarter ended June 2023, Heron Therapeutics (HRTX) reported revenue of $31.76 million, up 15% over the same period last year. EPS came in at -$0.35, compared to -$0.55 in the year-ago quarter.

The reported revenue represents a surprise of +0.04% over the Zacks Consensus Estimate of $31.75 million. With the consensus EPS estimate being -$0.23, the EPS surprise was -52.17%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Heron Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product sales- Sustol: $2.80 million versus $3.45 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.7% change.

  • Product sales- Aponvie: $0.30 million compared to the $1.20 million average estimate based on two analysts.

  • Product sales- Zynrelef: $4.20 million versus the two-analyst average estimate of $4 million.

  • Product sales- Cinvanti: $24.50 million compared to the $23.10 million average estimate based on two analysts. The reported number represents a change of +7.9% year over year.

View all Key Company Metrics for Heron Therapeutics here>>>

Shares of Heron Therapeutics have returned +14.4% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research